Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies

被引：0
|
作者：
Flinn, Ian W. [1 ]
Byrd, John C. [2 ]
Furman, Richard R. [3 ]
Brown, Jennifer R. [4 ]
Benson, Don M. [5 ]
Coutre, Steven E. [6 ]
Kahl, Brad S. [7 ]
Smith, B. Douglas [8 ]
Wagner-Johnston, Nina D. [9 ]
Spurgeon, Stephen E. [10 ]
Giese, Neill A. [11 ]
Yu, Albert S. [12 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Weill Cornell Med Coll, New York, NY USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Ohio State Univ, Div Hematol Oncol, Columbus, OH 43210 USA
[6] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[7] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Hematol Oncol Sect, Madison, WI USA
[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] Washington Univ, Sch Med, St Louis, MO USA
[10] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[11] Calistoga Pharmaceut Inc, Seattle, WA USA
[12] Calistoga Pharmaceut, Seattle, WA USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：380 / 380
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
    Hamlin, Paul A.
    Flinn, Ian W.
    Wagner-Johnston, Nina
    Burger, Jan A.
    Coffey, Greg P.
    Conley, Pamela B.
    Michelson, Glenn
    Leeds, Janet M.
    Der, Kenneth
    Kim, Yvonne
    Sabalvaro-Torres, Alice
    Birrell, Matt
    Pandey, Anjali
    Curnutte, John T.
    Patel, Manish R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (04) : E90 - E93
  • [32] Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
    Lenz, Georg
    Hawkes, Eliza
    Verhoef, Gregor
    Haioun, Corinne
    Thye Lim, Soon
    Seog Heo, Dae
    Ardeshna, Kirit
    Chong, Geoffrey
    Haaber, Jacob
    Shi, Wei
    Gorbatchevsky, Igor
    Lippert, Susanne
    Hiemeyer, Florian
    Piraino, Paolo
    Beckmann, Georg
    Pena, Carol
    Buvaylo, Viktoriya
    Childs, Barrett H.
    Salles, Gilles
    LEUKEMIA, 2020, 34 (08) : 2184 - 2197
  • [33] Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
    Georg Lenz
    Eliza Hawkes
    Gregor Verhoef
    Corinne Haioun
    Soon Thye Lim
    Dae Seog Heo
    Kirit Ardeshna
    Geoffrey Chong
    Jacob Haaber
    Wei Shi
    Igor Gorbatchevsky
    Susanne Lippert
    Florian Hiemeyer
    Paolo Piraino
    Georg Beckmann
    Carol Peña
    Viktoriya Buvaylo
    Barrett H. Childs
    Gilles Salles
    Leukemia, 2020, 34 : 2184 - 2197
  • [34] Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma
    Nastoupil, Loretta J.
    Neelapu, Sattva S.
    Davis, Eric
    Samaniego, Felipe
    Fowler, Nathan H.
    Westin, Jason R.
    Lee, Hun Ju
    Wang, Michael
    Hagemeister, Fredrick B.
    Beer, Philip
    Cecil, Alexander R. L.
    Dow, James
    McHale, Duncan
    Silva, Franck
    Ward, Penny
    Yavari, Arash
    Shuttleworth, Stephen Joseph
    BLOOD, 2019, 134
  • [35] PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients
    Iyengar, Sunil
    Clear, Andrew J.
    Owen, Andrew
    Maharaj, Lenushka
    Matthews, Janet
    Calaminici, Maria
    Auer, Rebecca
    Ghazaly, Essam
    Iqbal, Sameena
    Gribben, John G.
    Joel, Simon
    BLOOD, 2011, 118 (21) : 719 - 719
  • [36] Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
    Georg Lenz
    Eliza Hawkes
    Gregor Verhoef
    Corinne Haioun
    Soon Thye Lim
    Dae Seog Heo
    Kirit Ardeshna
    Geoffrey Chong
    Jacob Haaber
    Wei Shi
    Igor Gorbatchevsky
    Susanne Lippert
    Florian Hiemeyer
    Paolo Piraino
    Georg Beckmann
    Carol Peña
    Viktoriya Buvaylo
    Barrett H. Childs
    Gilles Salles
    Leukemia, 2024, 38 : 469 - 472
  • [37] ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)
    Forero-Torres, A.
    Akard, L. P.
    Wertheim, M. S.
    Phillips, T. J.
    Gutierrez, M. E.
    Edenfield, J. W.
    Caimi, P.
    Call, J.
    Persky, D. O.
    DeMarini, D. J.
    Zhou, L.
    Yeleswaram, S.
    Ramchandren, R.
    HAEMATOLOGICA, 2017, 102 : 249 - 249
  • [38] Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies
    Roschewski, Mark
    Farooqui, Mohammed
    Aue, Georg
    Mo, Clifton C.
    Valdez, Janet
    Soto, Susan
    Perez-Galan, Patricia
    Wilhelm, Francois
    Wiestner, Adrian
    BLOOD, 2012, 120 (21)
  • [39] Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies
    Roschewski, M.
    Farooqui, M.
    Aue, G.
    Wilhelm, F.
    Wiestner, A.
    LEUKEMIA, 2013, 27 (09) : 1920 - 1923
  • [40] Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies
    M Roschewski
    M Farooqui
    G Aue
    F Wilhelm
    A Wiestner
    Leukemia, 2013, 27 : 1920 - 1923
12345